Shattuck Labs is a clinical-stage biotechnology company that develops immunotherapy treatments for cancer and autoimmune diseases. The company's proprietary Agonist Redirected Checkpoint (ARC) platform is designed to activate the immune system's natural ability to fight cancer by targeting specific immune cells and receptors. Shattuck Labs' lead product candidate, SL-279252 (SRK-181), is a dual-targeting ARC that is being evaluated in Phase 1 clinical trials for the treatment of solid tumors. The company also has a pipeline of preclinical product candidates for the treatment of cancer and autoimmune diseases. Shattuck Labs was founded in 2016 and is headquartered in Brisbane, California.